Cargando…

A predictive model of overall survival in patients with metastatic castration-resistant prostate cancer

Metastatic castration resistant prostate cancer (mCRPC) is one of the most common cancers with a poor prognosis. To improve prognostic models of mCRPC, the Dialogue for Reverse Engineering Assessments and Methods (DREAM) Consortium organized a crowdsourced competition known as the Prostate Cancer DR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahmoudian, Mehrad, Seyednasrollah, Fatemeh, Koivu, Liisa, Hirvonen, Outi, Jyrkkiö, Sirkku, Elo, Laura L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2019
Materias:	Method Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556990/ https://www.ncbi.nlm.nih.gov/pubmed/31231503 http://dx.doi.org/10.12688/f1000research.8192.2

Ejemplares similares

Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients
por: Pölsterl, Sebastian, et al.
Publicado: (2017)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

Predicting survival time for metastatic castration resistant prostate cancer: An iterative imputation approach
por: Deng, Detian, et al.
Publicado: (2016)

ROTS: reproducible RNA-seq biomarker detector—prognostic markers for clear cell renal cell cancer
por: Seyednasrollah, Fatemeh, et al.
Publicado: (2016)

Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients
por: Wengel Mogensen, Søren, et al.
Publicado: (2016)

Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
por: Shiga, Motoki
Publicado: (2016)

Improved risk prediction of chemotherapy‐induced neutropenia—model development and validation with real‐world data
por: Venäläinen, Mikko S., et al.
Publicado: (2021)

End-of-life decisions guiding the palliative care of cancer patients visiting emergency department in South Western Finland: a retrospective cohort study
por: Hirvonen, Outi M., et al.
Publicado: (2018)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

Differential ATAC-seq and ChIP-seq peak detection using ROTS
por: Faux, Thomas, et al.
Publicado: (2021)

An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
por: Meier, Richard, et al.
Publicado: (2016)

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
por: Oh, William K., et al.
Publicado: (2017)

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
por: Holl, Eda K., et al.
Publicado: (2019)

Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
por: Une, Minami, et al.
Publicado: (2021)

Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
por: Hakozaki, Yuji, et al.
Publicado: (2023)

Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
por: Skaltsa, Konstantina, et al.
Publicado: (2016)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020)

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort
por: Rouyer, Magali, et al.
Publicado: (2019)

A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer
por: Seyednasrollah, Fatemeh, et al.
Publicado: (2017)

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
por: Shore, Neal D., et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer
por: Yang, Yun-Jie, et al.
Publicado: (2018)

Comparison of software packages for detecting differential expression in RNA-seq studies
por: Seyednasrollah, Fatemeh, et al.
Publicado: (2015)

Stable Iterative Variable Selection
por: Mahmoudian, Mehrad, et al.
Publicado: (2021)

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
por: Chi, K. N., et al.
Publicado: (2016)

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
por: Feyerabend, Susan, et al.
Publicado: (2019)

LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
por: Kumar, Gautam
Publicado: (2020)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
por: Chen, Hao Xiang, et al.
Publicado: (2023)

Erratum: Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy
por: Laajala, Teemu D., et al.
Publicado: (2017)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t20is2n2qq0s8kpof6virkdjm2